"Whether tolvaptan is a helpful long-term treatment in patients with ADPKD will depend on a balance between benefits and risks," state the authors.doi:10.1038/nrneph.2012.236Rebecca KelseyNature Reviews NephrologyKelsey R. Polycystic kidney disease: tolvaptan in ADPKD- TEMPO 3:4 trial results. ...
It will be interesting to know whether tolvaptan therapy can be initiated later in the course of disease in people who have polycystic kidney disease and whether the pretreatment rate of decline of GFR influences the response of tolvaptan. Clearly, given that this is such an expensive drug, it...
Called tolvaptan, the medication binds to receptors in the kidneys, blocking the hormones that cause cyst growth to slow progression. Your doctor can tell if it’s right for you.TAKE OUR FREE CLASS ON KIDNEY FAILURE TREATMENT If you have lupus nephritis and you’re diagnosed with kidney ...
E. et al. Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 trial. Nephrol. Dial. Transpl. 33, 477–489 (2018). CAS Google Scholar FDA. ...
and tolvaptan is the only FDA-approved drug that alleviates the symptoms of ADPKD. However, tolvaptan has only a modest effect on disease progression, and its long-term use is associated with many side effects. Therefore, there is still a pressing need to better understand the fundamental mechan...
The most common form, autosomal dominant polycystic kidney disease (ADPKD), is a disorder... PC Harris,VE Torres - 《Annual Review of Medicine》 被引量: 430发表: 2009年 Autosomal dominant polycystic kidney disease: recent advances in pathogenesis and treatment. Autosomal dominant polycystic kidney...
Tolvaptan Treatment and Long-Term Impact on Quality of Life in Autosomal Dominant Polycystic Kidney Disease Patients: A Pilot Study Long-term safety profile of tolvaptan in autosomal dominant polycystic kidney disease patients: TEMPO Extension Japan Trial. Drug Healthc Patient Saf. 2017;... Carraro,...
The Efficacy, the Treatment Response and the Aquaretic Effects of a Three-Year Tolvaptan Regimen in Polycystic Kidney Disease Patients... V Gkika,M Louka,M Tsagkatakis,... - 《Clinics & Practice》 被引量: 0发表: 2023年 Tolerability of Aquaretic-Related Symptoms Following Tolvaptan for Autosom...
Autosomal dominant polycystic kidney disease Emerging Drugs • GLPG2737: Galapagos NV • Bardoxolone methyl: Reata Pharmaceuticals • Jynarque/Jinarc/Samsca (tolvaptan): Otsuka Pharmaceutical • Tesevatinib/KD019: Sanofi • RGLS8429: Regulus Therapeutics...
Tolvaptan, an oral vasopressin V2 receptor (V2R) antagonist which lowers [cAMP]i to slow cyst growth and delay loss of kidney function, has been recently approved as the first disease-modifier drug for treatment of ADPKD in multiple countries [13,14]. Although pharmacological mTORC1 inhibition ...